Alight appoints Siobhan Nolan Mangini to Board; reclassifies directors for NYSE compliance

Alight, Inc. / Delaware

Siobhan Nolan Mangini appointed to Board effective Jan 1, 2024; brings healthcare and financial leadership experience from NGM Biopharmaceuticals and Castlight Health.
Directors Kausik Rajgopal and Denise Williams resign and reappointed to different classes to balance board size, effective same date.
Post-rebalancing: Class I – Meinhardt, Paolillo, Rajgopal; Class II – Henson, Massey, Scholl; Class III – Foley, Nolan Mangini, Williams.
Nolan Mangini is independent and expected to join the Audit Committee; director compensation unchanged.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Siobhan Nolan Mangini

Director

ALIT · Alight, Inc. / Delaware

Effective: 2024-01-01
Filed: December 11, 2023, 6:59 PM ET

On December 7, 2023, the Board of Directors (the “Board”) of Alight, Inc. (the “Company”) appointed Siobhan Nolan Mangini to the Board, effective as of January 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Siobhan Nolan Mangini was appointed as Director at Alight, Inc. / Delaware.

Action: appointed
Role: Director

Exact text from the filing

On December 7, 2023, the Board of Directors (the “Board”) of Alight, Inc. (the “Company”) appointed Siobhan Nolan Mangini to the Board, effective as of January 1, 2024.

View on SEC.gov

Alight, Inc. / Delaware filing history →

Source: SEC EDGAR

accession 0000950170-23-069198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.